1174046-84-4

Usage

Uses

Used in Pharmaceutical Research and Development:
Ethyl 4-Ethoxy-2-oxo-1,2-dihydropyridine-3-carboxylate is used as a research compound for drug discovery and medicinal chemistry due to its potential in the synthesis of new drugs with therapeutic benefits.
Used in Cardiovascular Disease Treatment:
Ethyl 4-Ethoxy-2-oxo-1,2-dihydropyridine-3-carboxylate is used as a potential treatment for cardiovascular diseases, leveraging its antihypertensive, antioxidant, and calcium channel blocking properties to improve patient outcomes.
Used in Drug Synthesis:
Ethyl 4-Ethoxy-2-oxo-1,2-dihydropyridine-3-carboxylate is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of novel drugs with potential applications in various medical conditions.
Used in Antioxidant Applications:
Ethyl 4-Ethoxy-2-oxo-1,2-dihydropyridine-3-carboxylate is used as an antioxidant agent, providing protection against oxidative stress and contributing to the prevention and treatment of various diseases.
Used in Calcium Channel Blocking Applications:
Ethyl 4-Ethoxy-2-oxo-1,2-dihydropyridine-3-carboxylate is used as a calcium channel blocker, helping to regulate calcium ion flow in cells and potentially treating conditions related to calcium imbalance.

Upstream product

• 78-39-7 Triethyl orthoacetate 
• 105-56-6 ethyl 2-cyanoacetate 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 
• 35260-93-6 ethyl 2-cyano-3-ethoxybut-2-enoate 
• 1345855-03-9 2-cyano-5-(dimethylamino)-3-ethoxypentyl-2,4-dienoic acid ethyl ester 

Downstream Products

• 1174046-87-7 4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid ethyl ester 
• 1174046-90-2 4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid 
• 1345855-09-5 4-ethoxy-1-(4-fluoro-phenyl)-2-oxo-1,2-dihydropyridine-3-carbonyl chloride 
• 1345855-10-8 N-(2,5-difluoro-4-(3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1345855-12-0 N-(5-chloro-2-fluoro-4-(3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1345855-15-3 N-(4-(2-[bis[(1,1-dimethylethoxy)carbonyl]amino]-3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-2,5-difluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1345855-16-4 N-(4-(2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-2,5-difluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1345855-17-5 N-(4-(3-bromopyridin-4-yloxy)-2,5-difluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1345855-18-6 N-(4-(3-(1H-pyrazol-4-yl)pyridin-4-yloxy)-2,5-difluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1439877-68-5 N-(2,5-difluoro-4-((2-propionamidopyridin-4-yl)oxy)phenyl)-4-(ethoxy-d5)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1439877-40-3 N-(4-((2-acetamidopyridin-4-yl)oxy)-5-chloro-2-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 

Relevant academic research and scientific papers

BIOMARKER-BASED THERAPEUTIC COMPOSITION

The present invention provides an anticancer agent for treating a patient who is resistant to a protein kinase inhibitor, the anticancer agent comprising, as an active ingredient, a thienopyridine derivative compound or a pharmaceutically acceptable salt thereof. Here, the patient may be a patient carrying active RON. In addition, the patient may be a patient carrying normal KRAS. In addition, the anticancer agent may be applied to a patient who is resistant to an EGFR inhibitor. In particular, the anticancer agent may be usefully used to treat a patient who is resistant to the therapeutic agent cetuximab.

Aromatic ring dioxane quinazoline or quinoline compound, composition and application of aromatic ring dioxane quinazoline or quinoline compound

The invention relates to a novel compound serving as an inhibitor of kinase such as TRK, c-MET, AXL, MER and/or VEGFR2, a composition and application of the novel compound. Specifically, the inventionprovides a compound (as shown in formula (1)) or an isomer, a solvate, a hydrate, a pharmaceutically acceptable salt and a prodrug thereof, and a pharmaceutical composition containing the compound, wherein the compound has the activity of strongly inhibiting kinase such as TRK, c-MET, AXL, MER and/or VEGFR2. The invention further discloses application of the compound or the pharmaceutical composition in preparation of a medicine. The medicine is used for treating autoimmune diseases or cancers.

HISTONE ACETYLTRANSFERASE MODULATORS AND COMPOSITIONS AND USES THEREOF

Compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.

THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

A thienopyridine derivative compound represented by Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions comprising same can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase.

THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Since a thienopyridine derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof of the present invention has an excellent effect of inhibiting protein kinase activity, a pharmaceutical composition comprising the same can be usefully used for preventing or treating diseases related to protein kinase activity.COPYRIGHT KIPO 2020

Protein kinase inhibitors comprising a pyrrolopyridazine derivative

The present invention relates to a pyrrolopyridazine derivative represented by chemical formula 1, or a pharmaceutically acceptable salt of the same. A compound according to the present invention and a pharmaceutically acceptable salt of the same can be u

Protein kinase inhibitors comprising a pyrrolopyridazine derivative

The present invention relates to a pyrrolopyridazine derivative represented by Formula 1 of the detailed description, or a pharmaceutically acceptable salt thereof. The compound according to the present invention and a pharmaceutically acceptable salt the

PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE

The present invention relates to a pyrrolopyridazine derivative represented by Formula 1 of the detailed description, or a pharmaceutically acceptable salt thereof. The compound according to the present invention and a pharmaceutically acceptable salt the

PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Formula (I). Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.

PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.